Boardroom Alpha
Boardroom Alpha
ALKS · Current Report (Form 8-K) · Filed May 20, 2026

Alkermes PLC — Current Report (Form 8-K)

Form
8-K
Filed
May 20, 2026
Period
May 20, 2026
Ticker
ALKS
Accession
0001193125-26-232584
Boardroom Alpha · Filing insights

Alkermes plc shareholders approved increasing the 2018 Stock Option and Incentive Plan's authorized shares by 5,900,000.

About Alkermes PLC
Market cap
$6.9B
1Y TSR
+24.3%
3Y TSR
+7.5%
Board grade
B-
Sector
Healthcare
CEO
Blair Curtis Jackson
Last annual meeting: May 20, 2026 · View full Alkermes PLC profile →
8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 20, 2026

ALKERMES PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

 

Ireland

 

001-35299

 

98-1007018

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

 

 

 

 

 

Connaught House, 1 Burlington Road

Dublin 4, Ireland D04 C5Y6

(Address of principal executive offices)

 

Registrant's telephone number, including area code: + 353-1-772-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Ordinary shares, $0.01 par value

 

ALKS

 

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 20, 2026, at the 2026 annual general meeting of shareholders (the “Annual Meeting”) of Alkermes plc (the “Company”), the Company’s shareholders approved amendments to the Alkermes plc 2018 Stock Option and Incentive Plan to, among other things, increase the number of the Company’s ordinary shares authorized for issuance thereunder by 5,900,000 (the plan as so amended, the “2018 Plan”).

The principal features of the 2018 Plan are summarized on pages 57-61 of the Company’s definitive proxy statement for the Annual Meeting filed with the U.S. Securities and Exchange Commission on April 6, 2026. That summary and the foregoing description are not intended to be complete and are qualified in their entirety by reference to the full text of the 2018 Plan, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 20, 2026, the Company held its Annual Meeting. The final voting results for the Annual Meeting are as follows:

1.
By separate resolutions, shareholders elected the following directors, each to serve on the Company’s board of directors (the “Board”) for a one-year term until the Company’s 2027 annual general meeting of shareholders, with the votes cast as follows:

For:

Against:

Abstain:

Broker Non-Votes:

Shane M. Cooke

135,495,689

5,523,691

150,595

7,911,628

Richard B. Gaynor, M.D.

139,207,401

1,903,354

59,220

7,911,628

Cato T. Laurencin, M.D., Ph.D.

139,953,548

1,159,431

56,996

7,911,628

Nancy S. Lurker

133,906,559

6,588,027

675,389

7,911,628

Brian P. McKeon

136,233,419

4,722,973

213,583

7,911,628

Richard F. Pops

139,164,715

1,939,528

65,732

7,911,628

Nancy L. Snyderman, M.D.

138,884,522

2,223,746

61,707

7,911,628

Frank Anders Wilson

135,804,853

5,204,570

160,552

7,911,628

Christopher I. Wright, M.D., Ph.D.

139,003,329

2,096,466

70,180

7,911,628

 

2.
Shareholders approved, in a non-binding, advisory vote, the compensation of the Company’s named executive officers, with the votes cast as follows: 139,234,176 votes for; 1,787,311 votes against; 148,488 votes abstaining; and 7,911,628 broker non-votes.
3.
Shareholders ratified, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company, and authorized, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm’s remuneration, with the votes cast as follows: 146,222,286 votes for; 2,812,663 votes against; and 46,653 votes abstaining.
4.
Shareholders approved the 2018 Plan, with the votes cast as follows: 128,147,910 votes for; 12,952,836 votes against; 69,229 votes abstaining; and 7,911,628 broker non-votes.
5.
Shareholders renewed Board authority to allot and issue shares under Irish law, with the votes cast as follows: 148,661,934 votes for; 382,138 votes against; and 37,531 votes abstaining.
6.
Shareholders renewed Board authority to disapply the statutory pre-emption rights that would otherwise apply under Irish law, with the votes cast as follows: 146,903,611 votes for; 2,086,009 votes against; and 91,983 votes abstaining.

 

2


 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

EXHIBIT INDEX

 

Exhibit No.

 

Description

10.1

 

Alkermes plc 2018 Stock Option and Incentive Plan, as amended.

104

 

Cover page interactive data file (embedded within the Inline XBRL document).

 

 

3


 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ALKERMES PLC

 

 

Date: May 20, 2026

By:

 

/s/ David J. Gaffin

 

 

 

David J. Gaffin

 

 

 

Secretary

 

4


From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Alkermes PLC (ALKS)

Reference

Frequently asked questions

When did Alkermes PLC file this 8-K?
Alkermes PLC (ALKS) filed this Current Report (Form 8-K) with the SEC on May 20, 2026. The accession number assigned by EDGAR is 0001193125-26-232584.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Alkermes plc shareholders approved increasing the 2018 Stock Option and Incentive Plan's authorized shares by 5,900,000. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Alkermes PLC's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Alkermes PLC has filed under CIK 1520262, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer